Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative cost‐effectiveness of neoadjuvant chemotherapy regimens for muscle‐invasive bladder cancer: Results according to VESPER data
Authors
Keywords
-
Journal
CANCER
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-10-18
DOI
10.1002/cncr.34502
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Comprehensive Approach to Clinical Staging of Bladder Cancer
- (2022) Przemysław Adamczyk et al. Journal of Clinical Medicine
- Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial
- (2022) Christian Pfister et al. JOURNAL OF CLINICAL ONCOLOGY
- Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer
- (2021) Ali Raza Khaki et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- 652O Dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (dd-MVAC) or gemcitabine and cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC): Results of the GETUG/AFU VESPER V05 phase III trial
- (2021) C. Pfister et al. ANNALS OF ONCOLOGY
- Identifying the Optimal Number of Neoadjuvant Chemotherapy Cycles in Patients with Muscle Invasive Bladder Cancer
- (2021) David D'Andrea et al. JOURNAL OF UROLOGY
- An economic analysis comparing health care resource use and cost of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin versus gemcitabine and cisplatin as neoadjuvant therapy for muscle invasive bladder cancer
- (2021) K. Montazeri et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Health-related Quality of Life for Patients Undergoing Radical Cystectomy: Results of a Large Prospective Cohort
- (2021) Matthew B. Clements et al. EUROPEAN UROLOGY
- Editorial Comment
- (2021) Brendan Connell et al. JOURNAL OF UROLOGY
- European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
- (2020) J. Alfred Witjes et al. EUROPEAN UROLOGY
- Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
- (2020) Jacqueline Vuky et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder
- (2020) Stefano Luzzago et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses
- (2020) Christian Pfister et al. EUROPEAN UROLOGY
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
- (2020) Thomas Powles et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Natural History of Untreated Muscle Invasive Bladder Cancer
- (2019) Alberto Martini et al. BJU INTERNATIONAL
- Longitudinal patterns of cost and utilization of medicare beneficiaries with bladder cancer
- (2019) Frank A. Sloan et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Long-term Oncological Outcomes from an Early Phase Randomised Controlled Three-arm Trial of Open, Robotic, and Laparoscopic Radical Cystectomy (CORAL)
- (2019) Muhammad Shamim Khan et al. EUROPEAN UROLOGY
- Modelling cost-effectiveness of a biomarker-based approach to neoadjuvant chemotherapy for muscle-invasive bladder cancer
- (2018) Yair Lotan et al. BJU INTERNATIONAL
- National Health Expenditure Projections, 2017–26: Despite Uncertainty, Fundamentals Primarily Drive Spending Growth
- (2018) Gigi A. Cuckler et al. HEALTH AFFAIRS
- Trajectories of Injectable Cancer Drug Costs After Launch in the United States
- (2018) Noa Gordon et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant Dose Dense MVAC versus Gemcitabine and Cisplatin in Patients with cT3-4aN0M0 Bladder Cancer Treated with Radical Cystectomy
- (2018) Homayoun Zargar et al. JOURNAL OF UROLOGY
- Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
- (2018) Charles C. Peyton et al. JAMA Oncology
- Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline
- (2017) Sam S. Chang et al. JOURNAL OF UROLOGY
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
- (2017) Joaquim Bellmunt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold
- (2014) Peter J. Neumann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cost-effectiveness of neoadjuvant chemotherapy before radical cystectomy for muscle-invasive bladder cancer
- (2014) Scott M. Stevenson et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
- Projections of the Cost of Cancer Care in the United States: 2010-2020
- (2011) A. B. Mariotto et al. JNCI-Journal of the National Cancer Institute
- A Markov Model Assessing the Effectiveness and Cost-Effectiveness of FOLFOX Compared With FOLFIRI for the Initial Treatment of Metastatic Colorectal Cancer
- (2010) John W. Tumeh et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Validation of the AJCC TNM Substaging of pT2 Bladder Cancer: Deep Muscle Invasion Is Associated with Significantly Worse Outcome
- (2010) Derya Tilki et al. EUROPEAN UROLOGY
- Disease-Free Survival at 2 or 3 Years Correlates With 5-Year Overall Survival of Patients Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer
- (2010) Guru Sonpavde et al. JOURNAL OF UROLOGY
- Cost-effectiveness analysis of immediate radical cystectomy versus intravesicalBacillusCalmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer
- (2009) Girish S. Kulkarni et al. CANCER
- Radical Cystectomy for Carcinoma of the Bladder: 2,720 Consecutive Cases 5 Years Later
- (2008) Mohamed A. Ghoneim et al. JOURNAL OF UROLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now